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Abstract
Background: The importance of accurate and affordable mutation calling in fixed pathology samples is becoming
increasingly important as we move into the era of personalised medicine. The Affymetrix OncoScan® Array platform
is designed to produce actionable mutation calls in archival material.
Methods: We compared calls made using the OncoScan platform with calls made using a custom designed PCR
panel followed by next-generation sequencing (NGS), in order to benchmark the sensitivity and specificity of the
OncoScan calls in a large cohort of fixed tumour samples. 392 fixed, clinical samples were sequenced, encompassing
641 PCR regions, 403 putative positive calls and 1528 putative negative calls.
Results: A small number of mutations could not be validated, either due to large indels or pseudogenes impairing
parts of the NGS pipeline. For the remainder, if calls were filtered according to simple quality metrics, both sensitivity
and specificity for the OncoScan platform were over 98%. This applied even to samples with poorer sample quality
and lower variant allele frequency (5–10%) than product claims indicated.
Conclusions: This benchmarking study will be useful to users and potential users of this platform, who wish to
compare technologies or interpret their own results.
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Background
With the increasing role of genomic information in both
diagnostic and research settings, the importance of
accessing this information in as wide a range of samples
as possible is also increasing. For cancer patients,
tumour resections and biopsies are typically examined
and then stored as formalin-fixed paraffin-embedded
(FFPE) sample. This has lead to huge archives of FFPE
material worldwide, estimated to number over one bil-
lion samples [1]. Although storing samples in this way
preserves tissue morphology in a manner optimised for
microscopic analysis, it has adverse effects on DNA
quality, which can preclude those samples being suitable
for some genomic analyses, unless suitable modifications
to protocols are made [2]. Typical FFPE artefacts of nu-
cleic acids include C > T base substitutions by deamin-
ation of cytosine to uracil, yielding thymine during PCR
amplification, and strand breaks. C > T base substitu-
tions result in false genotyping calls while DNA strand
breaks create greater difficulties at the assay level, redu-
cing the already low amounts of viable DNA from FFPE
for capture/amplification, sometimes to the point of total
assay failure. The alternative, fresh frozen tumour tissue,
produces high quality DNA that is more suitable for mo-
lecular tests but at the additional cost of cold storage, and
upheaval of established sample processing pipelines [3, 4].
It is becoming increasingly recognised that both som-
atic point mutations and genomic copy number changes
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have roles in the development of different cancer types
[5]. Given the small yields of viable DNA frequently ex-
tracted from FFPE samples, researchers often have to
make choices over which assays to perform to extract
the most useful information from each sample. As such
the OncoScan® FFPE Assay Kit (OncoScan assay) has
been developed to generate whole genome copy number
(CN), loss of heterozygosity (LOH) and putative somatic
mutation (SM) data from as little as 80 ng input DNA
(and can frequently work with as little as 40 ng) from
highly degraded FFPE samples. The assay currently de-
tects 74 clinically actionable SMs commonly found in
nine cancer genes and provides increased copy number
resolution in approximately 900 cancer genes to comple-
ment the genome wide CN data. Based on Molecular
Inversion Probe (MIP) [6] technology, the genomic
probes have a footprint of only 40 bp optimising them
for binding highly degraded DNA; a typical feature of
FFPE. Combined analysis of CN and a panel of SMs in a
single assay provides a convenient workflow suitable for
capturing a large portion of the underlying biology driv-
ing tumorigenesis.
We have previously described the validation of the
OncoScan assay in a multi-centre reproducibility study
of 162 FFPE tumour samples from a wide range of tis-
sues [7], with greater than 95% whole genome CN and
LOH profiles agreement between cross-site technical
triplicates. SM concordance between sites was found to
be 97%. We have also confirmed specific genomic CN
events using fluorescent in-situ hybridisation [8]. The
performance of the OncoScan SM calling algorithm has
already been tested in ideal conditions during product
development. To better understand how the assay would
perform using real world samples, the purpose of this
current study is to validate and compare as many of the
74 clinically actionable SMs on the OncoScan array as
possible in a wide range of clinical samples, using next-
generation sequencing technology.
Methods
Samples
As part of a wider project to assess the clinical utility of
the OncoScan FFPE assay (7), 2300 FFPE tumour sam-
ples were collected through Pathology and Tumour Biol-
ogy, University of Leeds and from the West Midlands
Regional Genetics Laboratory (WMRGL) from the
Human Biomaterials Resource Centre at the University
of Birmingham.
Sample collection, DNA extraction and handling pro-
tocols upstream of the OncoScan assay were not stan-
dardised between centres so as to better reflect the
diversity of “real world” FFPE material in clinical set-
tings. Fixed samples from varying ages up to 23 years
were used, including a number of different tumour
types: colorectal, breast, ovarian, melanoma, prostate,
lung, endometrial, bladder, vulva, upper gastro-intestinal
tract and pancreas. DNA was extracted using the
QIAamp DNA FFPE Tissue Kit, or the QIAamp DNA
micro kit (QIAGEN) following the recommended proto-
cols and according to the standard operating procedures
of each lab.
OncoScan assay
Samples were prepared for, and run on the OncoScan
assay following the manufacturers’ instructions [7].
Array fluorescence intensity data (CEL files), generated
by Affymetrix® GeneChip® Command Console® (AGCC)
Software version 4.0 were processed using OncoScan
Console software version 1.1.034 to produce OSCHP
files and a set of QC metrics.
Genomic copy number and aberrant cell fraction were
calculated by the provided “TuScan” algorithm, which
infers tumour cell content and ploidy from the distribu-
tions of the most common copy number and germline
minor allele frequencies, based on the principles used in
ASCAT [9].
Samples were then stratified by High Confidence SM
calls (as determined by the OncoScan algorithm). Sam-
ples were subsequently filtered by OncoScan QC met-
rics, specifically Median of Absolute Pairwise Difference
(MAPD) and normal diploid SNP QC (ndSNPQC). The
derivation of these metrics is explained in the supplement.
Those satisfying MAPD < = 0.3 and ndSNPQC > = 35
were considered “in bounds” and high quality. Those with
MAPD < = 0.3 and ndSNPQC > = 26 but < 35 were con-
sidered “in bounds” but borderline quality. The rest were
considered “out of bounds”. For each SM up to 22 sam-
ples were randomly selected from the “in bounds”
stratum. In some cases DNA extracted for the OncoScan
assay was no longer available in the required amount for
use by NGS. Rather than re-extract DNA from new sec-
tions and confound results by intra-tumour heterogeneity,
these samples were excluded and replacements randomly
selected again. Where 22 samples were not available due
to lower frequency of SM within the tumours sampled
over the duration of the project, the remaining samples
were selected from the “out of bounds” stratum and anno-
tated as such. 10 μl at 10 ng/μl of DNA from selected
samples was plated ready for NGS. A total of 392 samples
were chosen. This selection process is illustrated in the
Additional file 2: Figure S1.
NGS testing
A targeted panel of PCR primers covering all the SMs
on the OncoScan panel was designed using Primer3
[10]. Each SM was covered by two separate PCR primer
pairs to allow for redundancy and internal validation.
Primer details are given in the Additional file 2.
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Each DNA sample was amplified with PCR primers
chosen to capture both a putative SM, and a putative
wild type region. It was initially attempted to perform
PCR with a proof reading enzyme, but a large number of
samples did not produce enough PCR product to con-
vert to sequencing libraries. Therefore, PCR was per-
formed using Amplitaq Gold Fast PCR master mix
(Applied Biosystems). The four (or more) PCR products
from each sample (complimentary pairs for the putative
positive and negative SMs) were pooled in equimolar
amounts and prepared for NGS using NEBNext Ultra li-
brary preparation kits (New England Biolabs) with cus-
tom designed index tags to identify each sample. The
samples were sequenced on four runs of an Illumina
MiSeq using paired 150 bp reads.
Following sequencing and de-multiplexing, adapters
were removed using Cutadapt 1.9.1 [11]. Sequences
were aligned to the human genome version hg19
using BWA 0.7.12 [12], and processed using GATK
3.4-46 [13]. Using the Pysam wrapper for Samtools
[14], aligned reads were split into separate files ac-
cording to whether their coordinates matched those
of the expected PCR products. Variants were called
using VarScan 2.4.1 [15]. The entire NGS analysis
pipeline is available in the Additional file 2. Read
depth of over 100 and variant allele frequency (VAF)
of > = 5% were initially used as filters for VarScan SM
calls. OncoScan and VarScan SM calls were then
compared, with discrepancies manually checked by
examining raw read data.
Results
In total, 392 samples were sequenced, covering 641 PCR
regions. Between them, this tested 403 putative positive
SM calls and 1528 putative negative calls. A mean se-
quencing depth of 81843 was obtained (median 65832).
All sequencing results, together with comparisons to
the OncoScan SM calls are shown in Additional file 1.
Sequencing performance is summarised in Additional
file 2: Table S2, showing number of reads, mismatches,
and proportion of C > T mismatches.
Using the Affymetrix QC guidelines, 150 samples
passed QC with high quality, 117 were borderline and
125 were “out of bounds”.
Five samples produced no reads for one of their PCR
pairs, so those SM calls were excluded. After the design
process, it was discovered that one of the primers cover-
ing TP53:p.R273C/S:c.817C > T/A and TP53:p.R273H/
L:c.818G > A/T overlapped the mutation site, ensuring
that the primer, and not the genomic DNA was being se-
quenced. Those SM calls were also excluded from fur-
ther analysis. In total, 35 putative positive calls and 100
putative negative calls were excluded, resulting in 368
and 1428 respective calls remaining.
The remaining calls were classed as concordant posi-
tive (both OncoScan and NGS called the mutation), dis-
crepant positive (a mutation was initially called by
OncoScan, but not by NGS), concordant negative
(neither methods called a mutation), and discrepant
negative (OncoScan did not call a mutation, but NGS
did). Eight OncoScan positive calls were called as posi-
tive by VarScan, but were below the 5% threshold. Seven
of these had a VAF below 1%, while one (TSB01961) had
a VAF of 2.84%. One sample (TSB01476) was negative
according to OncoScan and the 5% VAF threshold, but
had been called by VarScan with a VAF of 1.43%.
The calls for each SM position are displayed in Fig. 1,
comparing all positive and negative calls and their agree-
ment or not with the NGS data, for all SMs and all SM
scores. It can be seen that very few OncoScan negative
calls were discrepant (9 out of 1528). Whilst there are
more discrepant OncoScan positive calls (55 out of 368),
these were not distributed randomly. It can be seen that
most discrepant positive calls had an SM score below
ten. Of the discrepant positives with a high SM score, al-
most all were either KRAS:p.G12A:c.35G > C or one of
eight large EGFR indels. The positive KRAS SMs agreed
with NGS in 6 out of 11 cases, meaning the NGS assay
was sometimes capable of calling this SM. However it
was clear that this was a badly performing SM either
from the point of view of the sequencing or OncoScan,
so these calls were excluded from further analysis. The
EGFR indels were so large that in most cases, one or
more of PCR, sequence alignment or mutation calling
was failing. Two of the 12 putative calls could be verified
with the standard NGS pipeline. Two more could be
found by searching through the unaligned reads for the
expected sequence. The remaining eight could not be
verified. Clearly these mutations could not be reliably
confirmed with the NGS approach, so were also ex-
cluded from further analysis.
For the remaining calls, the impact of the two sample
quality metrics, MAPD and ndSNPQC were compared
to discrepancy rate, along with the mutation specific SM
score. These were compared both visually as histograms
(Fig. 2), and statistically, using the Mann–Whitney test,
with a null hypothesis for each measure that the distri-
bution of discrepancies will be the same as the overall
distribution. As can be seen, MAPD had the smallest ef-
fect on positive calls (p = 0.002), ndSNPQC a slightly lar-
ger effect (p = 0.0003) while almost all discrepant
positive calls had a low SM score (p = 1.7 × 10−13). Only
five of the 256 OncoScan positive calls with an SM
score > = 10 were discrepant, whereas 37 of the positive
88 calls with an SM score < 10 were discrepant. There
were too few discrepant negative calls to make a rigor-
ous comparison, but it appeared that SM score was
again the biggest factor. (MAPD: p = 0.41; ndSNPQC:
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p = 0.82; SM score: p = 1.99 × 10−6). The effects of
these three metrics was further analysed by plotting
receiver operating characteristic (ROC) curves for
each (Fig. 3). Only the curve for SM score gets close
to the ideal value of a false positive score of 0 and a
true positive score of one. Corroborating our previous
observation that an SM score cut-off of ten was pos-
sibly better than the calculated cut-off near five, it is
at a score of 10 that the curve turns sharply.
As ndSNPQC had a moderate effect on discrepant
positive calls, and SM score a large effect, the combined
effects of these two metrics were plotted together (Fig. 4)
to investigate whether a combined metric would be
informative, and a subset of discrepant calls could be
better defined. It can be seen that most discrepant posi-
tive and negative calls have a relatively low ndSNPQC
score (less than 35, the defined high sample quality
cutoff ) and an SM score between 2 and 10. However it
should be noted that the factors influencing ndSNPQC
are partially related to the clarity of SM scores, and most
samples with an ndSNPQC above 35 have very few calls
of any type with SM scores between 2 and 10.
The numbers of OncoScan and NGS calls for the
whole assay and each SM position are summarised in
Tables 1 and 2 respectively. Up to this point, an un-
biased comparison of the two methodologies had been
used. However, to calculate sensitivity and specificity, for
the purposes of comparison, the NGS was temporarily
assumed to be the “true” result.
Table 1 shows that filtering calls by sample QC has a
small effect on sensitivity, but at the expense of discard-
ing large numbers of samples. Filtering by SM score has
a much bigger effect on sensitivity, and discards less
data. Table 2 expands this analysis for each SM, using
Fig. 1 Summary of SM scores for each mutation. Call type (concordant negative - grey, discrepant negative - orange, concordant positive – blue,
and discrepant positive - red) is represented by point colour, Possible or observed problematic SMs are labelled in red text, and discussed later
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Fig. 2 Distributions of SM scores, MAPD and ndSNPQC for positive and negative OncoScan calls. For positive calls (left), the proportions of
discrepant calls are shown in red. For negative calls (right), these numbers are stated, as they are too low to be displayed on the same scale
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Fig. 3 ROC curves for MAPD, ndSNPQC and SM score, showing their effect on putative positive calls. For MAPD, there was a simple pass/fail
threshold. For ndSNPQC, some samples were considered borderline quality. For SM score, “failed” calls were all called as negative for a mutation.
We imposed a borderline cut-off of ten based on results of previous analyses
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unfiltered data. This is repeated for the various filters in
the supplement (Additional file 2: Tables S4, S5 and S6).
Note that the calls with SM score between 5 and 10 are
excluded, rather than being called negative.
We also investigated whether SM score was linked
to VAF. The results are shown in Additional file 2:
Figure S2. It can be seen that there is a correlation, but
that it appears to be one way. Calls with a high SM score
have a high VAF, but calls with a high VAF do not always
have a high SM score. It can be seen that VAF was fre-
quently over 50%. This was not always indicative of high
tumour cell content. For instance, sample TSB02075 had
a KRAS mutation with a VAF of 58%. In this sample, the
region of the genome containing KRAS had two copies,
with a tumour cell content of 95%, which would lead to
an expected VAF of around 50%. Alternatively, sample
TSB00963 had a KRAS mutation with a VAF of 52%. In
this sample, there were three copies of the KRAS gene,
and a tumour cell content of 65%. If the mutation was in
the gained chromosomal copy, 100 cells from this sample
would contain 35 diploid normal cells, with 70 wild type
alleles, and 65 tumour cells, with 130 mutant alleles and
65 wild type. This gives a total of 130 mutant alleles and
135 wild type, close to the 52% VAF observed.
Discussion
With the increasing prevalence of genetic testing of tu-
mours, whether to guide treatment or to generate and
validate research hypotheses, the need for a cost effective
and reliable method of generating somatic mutation data
is becoming more important. Much of this testing will
be performed on either newly fixed pathological speci-
mens, or archival material which can be several years
old.
The objective of this study was to assess the perform-
ance of mutation calling in the OncoScan assay using a
range of real world FFPE clinical specimens, when com-
pared to an orthogonal method: next generation sequen-
cing of PCR products. At the most basic level, this can
be expressed as simple sensitivity and specificity. How-
ever, clinical DNA samples cover a range of different
levels of fixation damage, which will affect the perform-
ance of any assay. A secondary aim was to assess the
limits of this technology with regard to sample/data
quality, to answer when a user can trust their results,
and which results need to be validated by a second
method. In a diagnostic setting it is still commonplace
to validate any finding, but in a research setting, where
each individual patient is less important than the finding
of trends or patterns, such validation can place an in-
tolerable burden if performed on every putative result.
The OncoScan assay is designed to sequence action-
able mutations thought to be somatic in the absence of a
normal control. However, it is impossible to confidently
confirm mutations as truly somatic without comparisons
to matched normal tissue. The mutations in the OncoS-
can assay are thought to occur only rarely as germline
changes. The frequencies of these mutations in the
germline DNA of the Exome Aggregation Consortium
dataset (version 0.3.1) of over 60,000 individuals [16] re-
veals that the most common of these mutations occurs
at a frequency of less than 0.0001 in normal individuals,
with 43 of the mutations completely absent (Additional
file 2: Table S7). This indicates that, where discovered,
the mutations in this assay are unlikely to be germline.
Fig. 4 The combined effect of ndSNPQC and SM score on calling.
Again, call type is represented by colour. SM score is plotted
logarithmically, to allow clearer visualisation of the data
Table 1 Sensitivity and specificity calculations, assuming the NGS to be the true result. The calculation is shown with and without
filtering by sample QC or SM score
True negative False negative True positive False positive Sensitivity Specificity
All samples, all SMs 1121 9 302 42 0.88 0.99
All samples, SM score > 10 1121 9 251 5 0.98 0.99
Samples pass QC, all SMs 800 7 220 19 0.92 0.99
Samples pass QC, SM score > 10 800 7 192 2 0.99 0.99
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Table 2 Sensitivity and specificity calculations for all SMs compared, and overall. These calculations include all samples passing and
failing QC, and all SMs, no matter what SM score
SM TN FN TP FP Sensitivity Sensitivity.n Specificity Specificity.n
BRAF:p.G469A:c.1406G > C 2 0 2 1 0.67 3 1.00 2
BRAF:p.G469E:c.1406G > A 4 0 0 1 0.00 1 1.00 4
BRAF:p.V600E:c.1799 T > A 25 0 22 0 1.00 22 1.00 25
BRAF:p.V600K:c.1798_1799GT > AA 46 0 1 0 1.00 1 1.00 46
EGFR:p.G719A:c.2156G > C 6 0 0 0 NA 0 1.00 6
EGFR:p.G719C:c.2155G > T 1 0 0 5 0.00 5 1.00 1
EGFR:p.G719S:c.2155G > A 4 0 0 2 0.00 2 1.00 4
EGFR:p.L858R:c.2573 T > G 19 0 0 0 NA 0 1.00 19
EGFR:p.L861Q:c.2582 T > A 17 0 1 1 0.50 2 1.00 17
EGFR:p.T790M:c.2369C > T 1 0 1 0 1.00 1 1.00 1
IDH2:p.R140Q:c.419G > A 1 0 0 2 0.00 2 1.00 1
KRAS:p.G12C/S:c.34G > T/A 81 0 22 0 1.00 22 1.00 81
KRAS:p.G12D/V:c.35G > A/T 80 1 22 0 1.00 22 0.99 81
KRAS:p.G13D:c.38G > A 81 0 22 0 1.00 22 1.00 81
KRAS:p.Q61H:c.183A > C 6 0 2 4 0.33 6 1.00 6
KRAS:p.Q61H:c.183A > T 9 1 1 1 0.50 2 0.90 10
KRAS:p.Q61K/K:c.180_181TC > TA/AA 11 0 1 0 1.00 1 1.00 11
NRAS:p.G12D:c.35G > A 27 0 4 5 0.44 9 1.00 27
NRAS:p.G12S/C:c.34G > A/T 29 1 5 1 0.83 6 0.97 30
NRAS:p.G12V:c.35G > T 36 0 0 0 NA 0 1.00 36
NRAS:p.Q61K:c.181C > A 29 0 4 0 1.00 4 1.00 29
NRAS:p.Q61L:c.182A > T 32 0 1 0 1.00 1 1.00 32
NRAS:p.Q61R:c.182A > G 25 0 5 3 0.63 8 1.00 25
PIK3CA:p.E542K:c.1624G > A 18 0 22 0 1.00 22 1.00 18
PIK3CA:p.E545K:c.1633G > A 23 1 16 0 1.00 16 0.96 24
PIK3CA:p.H1047L:c.3140A > T 46 0 0 0 NA 0 1.00 46
PIK3CA:p.H1047R:c.3140A > G 29 1 13 3 0.81 16 0.97 30
PIK3CA:p.Q546K:c.1636C > A 38 0 2 0 1.00 2 1.00 38
PTEN:p.R130*:c.388C > T 1 0 0 0 NA 0 1.00 1
PTEN:p.R130G:c.388C > G 0 0 0 1 0.00 1 NA 0
PTEN:p.R130Q/fs*4:c.389G > A/delG 1 0 0 0 NA 0 1.00 1
PTEN:p.R159S:c.477G > T 6 0 0 2 0.00 2 1.00 6
TP53:p.C176F:c.527G > T 47 0 7 0 1.00 7 1.00 47
TP53:p.G245S/C:c.733G > A/T 31 1 15 2 0.88 17 0.97 32
TP53:p.H179R:c.536A > G 50 0 1 3 0.25 4 1.00 50
TP53:p.R175H:c.524G > A 33 0 21 0 1.00 21 1.00 33
TP53:p.R196*:c.586C > T 0 0 10 0 1.00 10 NA 0
TP53:p.R213*:c.637C > T 16 0 15 2 0.88 17 1.00 16
TP53:p.R248Q/L:c.743G > A/T 21 1 27 0 1.00 27 0.95 22
TP53:p.R248W:c.742C > T 47 1 1 0 1.00 1 0.98 48
TP53:p.R249S:c.747G > T 46 0 2 1 0.67 3 1.00 46
TP53:p.R282W:c.844C > T 45 1 13 0 1.00 13 0.98 46
TP53:p.R306*:c.916C > T 14 0 13 0 1.00 13 1.00 14
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While the OncoScan assay targets the most common
clinically actionable cancer mutations, many of these are
still very rare. The initial aim of this study was to valid-
ate all SMs with several putative positive and negative
samples, all passing QC filters. Despite a pool of 2300
individual tumours, and the relaxing of the sample cri-
teria to include those with out of bounds QC, only 49
positive SMs out of a possible 74 were testable. Many of
those which were tested had a single or very few puta-
tive positively called samples. Nevertheless, enough SMs
were tested in enough samples to obtain a detailed
breakdown of the performance of the technology.
One KRAS point mutation and eight EGFR indels ap-
peared to produce far more “high quality” discrepant
positive calls than the rest of the array. To prevent the
gross effects of these calls masking more subtle events
in the remaining well-performing SM sites, these calls
were not included in the remaining analyses. The EGFR
indels were very difficult to detect when performing
PCR and NGS, mainly due to the constraints of design-
ing PCR products less than 150 bp to allow the assay to
work in badly degraded DNA samples. Some discrepan-
cies were resolved by manually examining the raw reads
for the expected indels, but not all, suggesting that in
some cases the DNA fragments with indels were re-
moved during size selection, and that in other cases, the
indel comprised a considerable portion of the NGS read
length, making alignment and variant calling nearly im-
possible. The KRAS site has a nearly matching pseudo-
gene, which may also have been amplified by those PCR
primers. As such it is impossible to tell from these re-
sults whether the putative mutations called by OncoScan
are real, and the NGS is sequencing the pseudogene; or
false and the NGS is sequencing the gene. Four other
PCR primer pairs could be similarly affected by pseudo-
genes. Two of these, testing mutations in IDH2 and
PTEN were so rare that no samples were tested. One, test-
ing PTEN c.388 and c.389, only provided one positive call,
which was however, high quality but discrepant. The last,
testing PIK3CA c.1624-1636, produced 119 concordant
calls, and only one discrepancy, a putative negative call.
When designing array probes or PCR primers for use in
FFPE samples, short DNA fragments are a necessity. As
such pseudogenes remain a considerable problem for
some gene regions, no matter what technology is used.
When the effects of sample QC and SM score on the
concordance of calls were examined, a clear pattern
emerged. While not many discrepant negative calls were
observed, they ranked amongst the higher SM scores of
all the negative calls. In fact, all but one had higher SM
scores than any of the concordant negative calls from
the same samples. It may be that for several of those
calls, the mutation calling software almost called the
mutations, but that they fell just below the various
thresholds used. Similarly, the discrepant positive calls
were overwhelmingly found at the lower end of the SM
call range. Only five of 42 discrepant positive calls had
an SM score over 10, and only two had a score over 20.
One of those two was in the PTEN region which may
have been affected by a pseudogene. The other was
called as a TP53 c.488A > G by OncoScan but called as
A > C in the same position by NGS. Due to the way the
probes are designed, this probe could be labelled as de-
tecting A > C/G, but as it is currently labelled A > G, it
was called as a discrepancy.
MAPD had little discernable effect on concordance.
ndSNPQC did have an effect, albeit smaller than SM
score. When SM score and ndSNPQC were plotted to-
gether, it could be seen that samples with high
ndSNPQC had a bimodal distribution of SM calls, low
and high, with few calls in the 5–10 range where most
of the positive and negative discrepancies were found.
ndSNPQC is a measure of the clarity of the probe sig-
nals, specifically, the separation between the AA, AB
and BB signals for germline polymorphisms, with the ex-
pectation that clarity of signal for germline events will
be mirrored for putative somatic mutations. As such, the
lack of SM calls in high ndSNPQC samples with scores
between 5 and 10 is to be expected. The few SM calls in
this range that were seen in samples with high ndSNPQC
had similar levels of discrepancies as seen in the other
samples. An ndSNPQC over 26 is indicative of a sample
passing QC, and over 35 as being a high quality sample.
In terms of SM calling, this is simply an indication that
those samples are less likely to have SM calls in the SM
score range of 5 to 10, not that SM calls in that range are
more likely to be true in high quality samples. In fact,
from the point of view of calling SMs, samples well below
the sample QC metrics performed just as well, as long as
the SM score of each mutation is taken into account.
Table 2 Sensitivity and specificity calculations for all SMs compared, and overall. These calculations include all samples passing and
failing QC, and all SMs, no matter what SM score (Continued)
TP53:p.V157F:c.469G > T 4 0 3 0 1.00 3 1.00 4
TP53:p.Y163C:c.488A > G 3 0 3 1 0.75 4 1.00 3
TP53:p.Y220C:c.659A > G 30 0 2 1 0.67 3 1.00 30
Totals 1121 9 302 42 0.88 344 0.99 1130
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As this was a validation of the OncoScan platform,
when sensitivity and specificity calculations were per-
formed, the NGS calls were taken as being the true re-
sult. NGS has previously been shown to be able to
detect the same mutations in matched fresh and FFPE
samples in a range of conditions [4, 17]. When all calls
were tested, sensitivity was 88% and specificity 99%.
Restricting the analysis to samples passing QC did not
greatly change these values. Restricting to SM scores
above 10 gave sensitivity of 98% and specificity of 99%.
For the purposes of this comparison, calls with SM
scores between 5 and 10 were excluded, rather than be-
ing called negative. A negative call would simply give a
much higher false negative rate. In a research or clinical
setting, these samples would either be discarded, or
tested with an alternative method. Neither of the sensi-
tivity or specificity calculations were perfect. It was not
possible to tell, in the discrepant cases, which platform
was wrong. Sequencing was performed to high depth,
but in badly degraded DNA, sequencing to high depth
often results in sequencing the same few molecules,
complete with formalin-induced artefacts, multiple
times. A number of commercially available sequence
capture kits were trialled prior to this work being carried
out, but none produced libraries from enough samples
to be used in this analysis. Using two PCR products for
each mutation was an attempt to reduce the effects of
fixation damage being called as a genuine mutation. The
very small number of false negative calls suggested that
the NGS approach was not producing many errors. A
high sequence error rate would have lead to many sam-
ples being called negative by OncoScan and positive by
NGS.
These results were obtained by choosing OncoScan
calls and validating them using NGS. Different results
may have been obtained if the samples were chosen
based on NGS calls initially. Higher levels of concord-
ance may have been observed, as several of the samples
which, in this study, were marked as discrepant positive
calls, would have been called as negative by NGS, and
not selected for validation. Alternatively it may have
been the case that NGS is far more sensitive, and many
samples would have been selected with positive SM calls
by NGS, that OncoScan would have been unable to de-
tect. Most of the samples were sequenced for two re-
gions, one where a putative positive call was found, and
one with a putative negative call. As most of the samples
only had one mutation called, it may be the case that by
using samples which already had one positive call as a
putative negative sample for a different region, the study
was biased to include too few false negative samples. A
more perfect test would have been to randomly select
500 samples and sequence all regions. However, that
would mean few, or none of the rarer positive SM calls
were tested. In addition, these are all valuable clinical
samples being used in other studies, so use of DNA, and
transport of samples between sites was minimised as
much as possible.
The OncoScan array has been shown as being able to
detect putative somatic mutations down to a variant al-
lele frequency of 15% in beta testing. However, out of
the 302 concordant positive calls, 21 had a frequency
below 15%, as measured by NGS, with the lowest value
of 5.7%. Clearly in some circumstances, the array was
performing beyond its product claims. While mutations
present in such small proportions of cells may not be
important when deciding what is the driver mutation of
those tumours, they may become more important due to
the development of initially rare, treatment-resistant
sub-clones.
As well as SM information, OncoScan provides gen-
ome wide copy number and loss of heterozygosity data
at high resolution from archival clinical material. We
have previously shown that copy number events called
using OncoScan have high concordance with the same
events called using an orthogonal method [8].
Conclusions
In summary, the OncoScan assay gives reliable SM
calls, even in cases with poorer DNA quality, or
lower variant allele frequency than guaranteed. There
are a small number of SMs which could not be reli-
ably validated, either due to large indels which could
not be detected using the NGS pipeline, or potential
pseudogenes which may have affected either technol-
ogy. Calls in these regions should be treated with
caution, until more validation can be performed. The
SM score for each call is a good indicator of the reli-
ability of that call. Negative calls with a high SM
score and positive calls with a low score are much
less reliable than other calls, and should be validated
by alternate methods. This range of uncertain calls
does, however make up a minority of all calls, espe-
cially in good quality samples. Outside of this small
window, both sensitivity and specificity of the assay is
extremely high.
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